Cofactor and redox pathway
The clinical proposition concerns route, dose, compartment, salvage, active consumption and demonstrated response.
Clinical comparison · Bali
NAD+ or peptides: which clinical route fits the objective?
A physician-led comparison of NAD+ IV therapy and peptide protocols for energy, recovery, brain fog, metabolic health and cellular resilience.
For people in Bali deciding whether to discuss NAD+, a peptide pathway, a staged combination or a different starting point.See the physician-led NAD+ pathway →
NAD+ · IV metabolic cofactor
Peptides · pathway-specific signals
Baseline before sequence
One longitudinal record
Clinical route comparator
NAD+ and peptides answer different mechanistic questions.
The choice should follow the unresolved biological bottleneck, not the popularity of the intervention.
Molecule-specific signal
Each peptide has a separate sequence, target architecture, exposure and physiological boundary.
One interpretable change at a time
Staging pathways can make tolerance and response more attributable than an immediate multi-product stack.
The objective selects the route
Energy, tissue recovery, metabolic health and cognition create different causal questions and endpoints.
NAD+ and peptides do different jobs
NAD+ is a cellular cofactor central to redox and energy metabolism; Clinic Terrain administers it intravenously in physician-selected doses. Peptides are signalling molecules considered one by one against a defined objective. They are not interchangeable categories.
Choose from the objective, not the trend
Low energy, cognitive fatigue, tissue recovery, body composition and metabolic health create different clinical questions. History, medication, prior response, laboratory context and the time course determine which route deserves discussion first.
A sequence can be more useful than a stack
When more than one pathway is relevant, the physician can stage interventions and define review points. That makes tolerance and response interpretable. Combining therapies is a clinical decision, not an automatic upgrade.
Quality evidence follows both routes
The NAD+ route records dose, duration, setting and tolerance. The peptide route connects the exact proposed presentation, its matching documentation and protocol to the same living patient record. Each review begins with the exact intervention and observed trajectory.
WhatsApp can route the first decision
Send the main objective, current symptoms, relevant conditions and medication, previous NAD+ or peptide experience, recent laboratory data and your Bali location. The team can direct you to the appropriate consultation instead of selling a default product.
Connected clinical library
NAD+, from first question to monitored protocol.
Dose, duration, cost, evidence, tolerance and the clinical checks that connect them.
Direct answers
Questions this evidence can, and cannot, answer.
Is NAD+ better than peptides for energy?
There is no universal winner. Energy complaints can involve several systems, and the appropriate route depends on the clinical pattern, existing data and the objective being measured.
Can NAD+ and peptides be used in the same plan?
They may be considered in a staged plan when the physician finds a coherent rationale, defines the sequence and can follow tolerance and response.
Which route is faster to organise in Bali?
NAD+ IV and peptide consultation have different assessment and operational requirements. Share your location and objective on WhatsApp so the team can confirm the right starting point and timing.
Do I need blood tests first?
Not every decision requires the same tests. The physician reviews existing information and selects laboratory questions only when they can change the route or the follow-up plan.
Evidence position
NAD+ and peptides are distinct clinical routes. Mechanism, human evidence, product provenance and the patient’s objective must be considered separately before a sequence is chosen.
Sources used for this page
Human studyGrant et al.: intravenous NAD+ metabolome pilot (2019) ↗Direct six-hour IV NAD+ administration and measured metabolic changes; a small pilot, not proof of broad clinical benefit.Human studyReal-world IV NAD+ and IV NR tolerability pilot (2026) ↗Exploratory infusion duration, symptoms and short-term biomarkers; retrospective data, not an efficacy trial.Regulatory guidanceWHO: good storage and distribution practices for medical products ↗International principles for documented purchasing, receipt, storage, distribution and supply-chain integrity.Your first message · Where you are + what you need help with